Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. - Wikidata - wikimedia - TriplyDB

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

http://www.wikidata.org/entity/Q38199984

about

Hypoglycemic agents and potential anti-inflammatory activity New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders Vasculoprotection as a Convergent, Multi-Targeted Mechanism of Anti-AD Therapeutics and Interventions Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes Mononuclear cells and vascular repair in HHT User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.The contributions of dipeptidyl peptidase IV to inflammation in heart failure.DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.Circulating levels of apelin, glucagon-like peptide and visfatin in hypercholesterolemic-hyperhomocysteinemic guinea-pigs: their relation with NO metabolism.

P2860

Q26750414-F30C69E3-CF46-4090-86FE-E648F72CFB3D Q26777654-F7AE9C62-1B05-40F1-B862-1327CE0191D7 Q26781557-EA477501-7EC7-41C4-983F-3E6577F745DA Q26829634-9DBE5981-D0D6-4EF5-B4B7-BC4C96741880 Q26999386-080247F8-C938-4DDE-85FD-CCF11104548E Q28067465-7F58BD41-A726-4F6E-9941-637485BA3EC8 Q28084374-3147BC1D-C9BD-4A87-9906-3238DAF3EC35 Q38587097-0C35F86B-0645-48CC-9A82-66CDACF2E8B6 Q38692092-D8B9FCCF-AD05-4A5C-AE27-C2D0BB4C9DFB Q39741688-20A1EAA6-70C9-49A2-9A61-E083F62E69F5 Q39751432-7AE5E6AE-FD22-4006-84D6-C1A22C27D886 Q43054868-85C7DA70-800D-478E-BAF5-09083A2124C2 Q46379488-0DA0C70B-5DCF-4AF2-936C-65B4D5A1AE9E

P2860

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

http://www.wikidata.org/entity/Q38199984

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

@en

type

label

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

@en

prefLabel

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.

@en

P1433

Q38199984-BDF903D3-FD88-446A-A6DB-DA19D6291266

P1476

Q38199984-F2580469-FA35-401F-A179-F456FC9A0E8D

P2093

Q38199984-48BFC293-C0A5-4791-A6FF-230D050A3F81

Q38199984-7DE69128-EEA9-4ACF-9B73-8CA81A6A39DB

P2860

Q38199984-033DE0A6-A539-45D7-BB0A-6955B00C5846

Q38199984-059ABF23-D8E7-4B2C-A61A-DA975302C30D

Q38199984-08861D94-F6D1-40CF-B050-A888EE73EA16

Q38199984-0A84783D-1DB2-4294-8590-5941FAB3FAE9

Q38199984-11751537-0FCB-4E95-B246-0F7C130B5649

Q38199984-1230A2B2-E338-4BA9-B023-B4B735AFB126

Q38199984-14DE7782-9633-4F65-B841-D5FD46E96EF7

Q38199984-1B50C74A-569E-45DE-BA7B-3E991883FBD1

Q38199984-1B9BF855-C5FE-4EC1-9611-CAF47E134B2D

Q38199984-1F384D67-A2DE-4D9D-AB9E-FF3B97821C2A

P2888

Q38199984-9B7BE3BC-CB59-43D1-B2C0-ECAB886FDD3C

P304

Q38199984-ED5109BA-7214-4C18-BA08-D1504F8F3D97

P31

Q38199984-A27D7F91-4B70-42F2-A536-3EC741C917FB

P356

Q38199984-C74A0040-AD34-43AE-847E-60D365B1C100

P433

Q38199984-50D77DDB-E33C-44C4-9BCA-DABE2E900336

P478

Q38199984-4455B41B-7400-4E74-9CBE-3612BC86800D

P50

Q38199984-87C218E0-3161-482B-AEC1-F555E8719A12

P577

Q38199984-9E4BB65F-DD6B-451F-B457-E8F3DDD98C96

P6179

Q38199984-2CABE49E-BF9F-4446-9F1D-08B4FE953781

P698

Q38199984-B3928EE2-7AC7-45CC-B172-607B4F275E22

P921

Q38199984-8B16AD22-9208-437B-BA09-4E2EE5DDFF03

P356

S11892-014-0483-3

P1433

Current diabetes report

P1476

Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy

@en

P2093

Angelo Avogaro

http://www.w3.org/2001/XMLSchema#string

Saula Vigili de Kreutzenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

P2888

s11892-014-0483-3

P304

483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11892-014-0483-3

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Gian Paolo Fadini

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1031880884

http://www.w3.org/2001/XMLSchema#string

P698

24676508

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy